UniQure Wins a Surprise FDA Path in Huntington's, Moderna's mRNA Flu Vote, and a Record IPO Run – This Week in Biotech #105

Key Takeaways

• FDA accepts 3‑year Phase 1/2 data for uniQure's Huntington gene therapy
• Moderna's mRNA flu vaccine receives unanimous advisory panel support
• Jazz partners with AbCellera on T‑cell engagers, potential $4.1B deal
• Biogen to acquire RayThera, up to $1B for immunology expansion
• Kardigan's IPO raises $400M, shares jump 38% on debut

Pulse Analysis

The FDA’s recent pivots illustrate a nuanced regulatory stance that balances rigor with urgency. By allowing uniQure to file an accelerated approval based on a modest 50‑patient dataset, the agency acknowledges the dire lack of treatments for Huntington’s disease and the ethical challenges of sham surgery controls. This case sets a precedent for other rare, fatal conditions where traditional trial sizes are impractical, prompting sponsors to tailor data packages to disease severity rather than blanket standards.

Moderna’s mRNA flu vaccine, mFluSiva, marks a potential watershed for seasonal immunization. After an initial refusal earlier in the year, the advisory committee’s unanimous vote reflects growing confidence in mRNA’s rapid redesign capability, a critical advantage as influenza strains drift annually. Approval would not only diversify Moderna’s post‑COVID pipeline but also provide the U.S. market with a faster, more adaptable flu vaccine platform, potentially reshaping public‑health response strategies and opening doors for mRNA applications in other infectious diseases.

Beyond regulatory shifts, the biotech ecosystem is buoyed by vigorous M&A and a revitalized IPO market. Large caps like Biogen and Lilly are snapping up niche innovators to broaden modality portfolios ahead of looming Section 232 pharma tariffs, while platform collaborations such as Jazz‑AbCellera aim to de‑risk high‑potential but technically challenging assets. Kardigan’s strong debut underscores investor appetite for capital‑efficient, founder‑led companies. Collectively, these trends signal a robust funding environment that rewards strategic flexibility, innovative science, and clear pathways to market.